Cardiac diseases in AIDS prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Changes made per Mahshid's request)
 
(One intermediate revision by the same user not shown)
Line 12: Line 12:
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
[[CME Category::Cardiology]]


[[Category:Cardiology]]
[[Category:Cardiology]]
[[Category:Infectious disease]]
 
[[Category:Disease]]
[[Category:Disease]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Latest revision as of 17:19, 18 September 2017

Cardiac diseases in AIDS Microchapters

Home

Overview

Pathophysiology

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cardiac diseases in AIDS prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

slides

Images

American Roentgen Ray Society Images of Cardiac diseases in AIDS prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiac diseases in AIDS prevention

CDC on Cardiac diseases in AIDS prevention

Cardiac diseases in AIDS prevention in the news

Blogs on Cardiac diseases in AIDS prevention

Directions to Hospitals Treating Cardiac diseases in AIDS

Risk calculators and risk factors for Cardiac diseases in AIDS prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Overview

Statins and aspirin have shown to reduce mortality from CVD in general population, but their use in HIV infected population is uncertain.

Prevention

  • Various studies showed reduced mortality from CVD in HIV infected patients, but this effect was not found to be statistically significant. Statins are well tolerated in HIV infected populations, except for some side effects like myalgia and myopathies.
  • Use of aspirin has certainly reduced mortality in general population, but its use in HIV infected patients has not been implicated. Results from CVD prevention trials in HIV infected patients are needed.

References


Template:WikiDoc Sources CME Category::Cardiology